Temazepam
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Temazepam: From Insomnia to Sleep Disorder, Initiating and Maintaining Sleep
One-Sentence Summary
Temazepam is an internationally established benzodiazepine hypnotic; no original-indication text is available from New Zealand regulatory data because the drug is currently not marketed there. The TxGNN model predicts efficacy for sleep disorder, initiating and maintaining sleep (insomnia) with a 99.82% prediction score — notably, this is not a novel therapeutic area but the drug's long-established clinical use, supported by 0 registered clinical trials and 20 publications, including a completed 2024 Phase III RCT specific to temazepam.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from NZ regulatory data (drug not marketed); internationally documented as a short-term insomnia treatment (benzodiazepine hypnotic class) |
| Predicted New Indication | Sleep disorder, initiating and maintaining sleep (insomnia) |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L2 |
| New Zealand Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for this drug. Based on known information, temazepam is a member of the benzodiazepine class of hypnotic/sedative agents, whose efficacy in the treatment of insomnia has been proven through decades of clinical use and sleep-laboratory research, and mechanistically it is directly applicable to the predicted indication.
Importantly, the predicted new indication — "sleep disorder, initiating and maintaining sleep" — is essentially the drug's own long-established clinical use rather than a genuinely novel therapeutic area. Literature dating back to 1978 (PMID 342551) and 1984–1992 (PMID 6149491, 1319429) already documents temazepam's hypnotic efficacy, and a 2024 Phase III RCT (PMID 39304187) continues to evaluate it for insomnia in a specialized population (advanced cancer patients). The TxGNN prediction here should be read as confirmation of a known indication, and given that temazepam is not currently registered in New Zealand, the practical value of this signal is a potential market-entry opportunity for an already-validated hypnotic rather than a scientific repurposing discovery.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39304187 | 2024 | RCT | Journal of Palliative Medicine | Three-arm, double-blind, Phase III RCT of temazepam vs. melatonin vs. placebo for insomnia in advanced cancer patients |
| 39374004 | 2024 | RCT | JAMA Internal Medicine | Randomized trial of masked taper with behavioral intervention for discontinuing benzodiazepine receptor agonist hypnotics |
| 2859305 | 1985 | RCT (multicenter, double-blind) | Journal of Clinical Psychopharmacology | Compared midazolam and temazepam for sleep and residual performance when dosed mid-night; temazepam 30mg vs. placebo |
| 342551 | 1978 | Sleep laboratory study | Journal of Clinical Pharmacology | Evaluated temazepam 30mg for sleep induction/maintenance across short-, intermediate-, and long-term use |
| 6149491 | 1984 | Comparative study | Neuropsychobiology | Compared temazepam 40mg and flurazepam 30mg on sleep quality and residual performance in healthy subjects |
| 27998379 | 2017 | Clinical Practice Guideline | Journal of Clinical Sleep Medicine | AASM guideline on pharmacologic treatment of chronic insomnia, evaluating individual drugs including temazepam |
| 33249496 | 2021 | Systematic Review / Network Meta-analysis | Sleep | Compared efficacy and safety of hypnotics, including temazepam, for insomnia in older adults |
| 27751669 | 2016 | Review | Clinical Therapeutics | Reviewed safety and efficacy of sleep medications, including altered pharmacokinetics, in older adults |
| 30058034 | 2018 | Review | Drugs & Aging | Recommendations for pharmacological management of insomnia in elderly patients |
| 1319429 | 1992 | Review | The Journal of Clinical Psychiatry | Historical review of benzodiazepine hypnotic pharmacology, noting temazepam's shorter half-life replacing flurazepam |
New Zealand Market Information
Temazepam is currently not marketed in New Zealand — no product authorizations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA/package-insert warnings and contraindications, and DDI data, were flagged as a Blocking data gap (DG001) in the source evidence pack and could not be retrieved — this must be resolved before any S1 safety assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: While temazepam's efficacy for insomnia is well-established (including a completed 2024 Phase III RCT), the drug is not currently marketed in New Zealand and a Blocking data gap exists for package-insert warnings/contraindications — safety review (S1) cannot proceed without this. The predicted "new" indication is also essentially the drug's known use, so the primary decision here concerns market entry rather than indication expansion.
To proceed, the following is needed:
- TFDA/local regulatory package insert (warnings, contraindications) — required to clear the Blocking gap (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Drug-drug interaction (DDI) data (current query returned no results)
- Regulatory pathway assessment for New Zealand market entry, given zero existing authorizations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.